Martin Mueller‐Zsigmondy

FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms

Martin Siewert, Jennifer Dressman, Cynthia K. Brown et al. · AAPS PharmSciTech · 2003 · 370 citations · Full text

Pharmacy, Pharmaceutics, Dissolution Testing +15

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: <i>In Silico</i> and Clinical Evaluations

Tanay S. Samant, Shyeilla V. Dhuria, Yasong Lu et al. · Clinical Pharmacology & Therapeutics · 2017 · 81 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Setting accelerated dissolution test for PLGA microspheres containing peptide, investigation of critical parameters affecting drug release rate and mechanism

Ivana Tomic, Ana Vidis-Millward, Martin Mueller‐Zsigmondy et al. · International Journal of Pharmaceutics · 2016 · 60 citations

Pharmacy, Pharmaceutics, Pharmacokinetics +17

Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies

Tycho Heimbach, Filippos Kesisoglou, Jasmina Novaković et al. · Journal of Pharmaceutical Sciences · 2021 · 60 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption

Marc Laisney, Tycho Heimbach, Martin Mueller‐Zsigmondy et al. · Journal of Pharmaceutical Sciences · 2021 · 53 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16